Optibrium
Drug discovery software for pharmaceutical, biotech and academic teams designing and selecting small-molecule compounds
Highlights
- Hiring3 open roles
- New on EvolcAdded 2026-10-30
About Optibrium
Optibrium develops software for molecular design, optimisation and data analysis in drug discovery. Its products include StarDrop, Cerella, BioPharmics and Semeta, covering predictive modelling, AI-guided analysis, 3D molecular design and metabolism prediction.
Customers include pharmaceutical companies, biotech firms and academic teams. Optibrium sells software licences and provides onboarding, training and scientific support.
The company was founded in 2008 and is headquartered in Cambridge, UK. It opened a US subsidiary in Cambridge, Massachusetts, in 2022. Current roles include scientists, an application scientist and a platform engineer.
Product: Drug discovery software for compound design, optimisation, data analysis, AI-guided predictions, 3D molecular design and metabolism prediction.
Jobs at Optibrium (3)
Optibrium is hiring for 3 roles in customer support, data & AI and engineering. One is remote.
Application Scientist (Maternity Cover)
New on EvolcLead Platform Engineer
New on EvolcSenior or Principal Scientist – AL/ML
New on Evolc
Companies hiring like Optibrium
Leadership
- Edmund Champness · CSO and Company DirectorSource: company website
- Matthew Segall · CEO and Company DirectorSource: company website
- James Halle · Chief Commercial OfficerSource: company website
- Michelle Bendall · Chief Financial OfficerSource: company website
More biotech & pharma companies
Orchard Therapeutics
Develops hematopoietic stem cell gene therapies for severe genetic diseases, with patients, families and clinicians as its audienceRemote-friendlyOribiotech
Automated bioreactor and manufacturing platform for cell and gene therapy developers and manufacturersNew on EvolcOrthoson
Develops an injectable implant to restore spinal disc mechanics for people with degenerative disc disease and back painNew on EvolcOttimo Pharma
Clinical-stage biotech developing PD-1/VEGFR2 dual-paratopic antibodies for patients with cancerNew on EvolcOxsonics
Clinical-stage drug delivery company developing SonoTran, an ultrasound platform that boosts anti-cancer drug penetration into solid tumoursNew on EvolcPathios Therapeutics
Develops GPR65-targeting cancer immunotherapies for patients with solid tumorsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- HubSpot
- WordPress